You have 9 free searches left this month | for more free features.

bispecific

Showing 1 - 25 of 569

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Advanced Solid Tumors Trial in Guangzhou (MR001)

Not yet recruiting
  • Advanced Solid Tumors
  • Guangzhou, Guangdong, China
    Nanfang Hospital, Southern Medical University
Nov 12, 2023

Cancer Trial in Tuebingen (Bispecific antibodies (bsAB))

Available
  • Cancer
  • Bispecific antibodies (bsAB)
  • Tuebingen, Baden-Wuerttemberg, Germany
    University Hospital Tuebingen
Nov 2, 2022

B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma Trial in Beijing (CD19/CD22-bispecific CAR-T

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • +2 more
  • CD19/CD22-bispecific CAR-T cells
  • Beijing, Beijing, China
    Liang Wang
Oct 7, 2023

Colorectal Cancer Trial (Administration of CC-3)

Not yet recruiting
  • Colorectal Cancer
  • Administration of CC-3
  • (no location specified)
Aug 11, 2023

Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)

Terminated
  • Neuroblastoma
  • +2 more
  • Humanized 3F8 Bispecific Antibody
  • Blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 11, 2022

SCLC, Extensive Stage Trial in Shanghai (AK112, Etoposide, Carboplatin)

Recruiting
  • SCLC, Extensive Stage
  • Shanghai, Shanghai, China
    Shun Lu
Oct 12, 2022

Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)

Not yet recruiting
  • Advanced Prostate Cancer
  • Lyon, France
  • +2 more
Oct 18, 2023

Peripheral T-cell Lymphoma Trial in Beijing (AK104)

Terminated
  • Peripheral T-cell Lymphoma
  • AK104
  • Beijing, Beiing, China
    Beijing Cancer Hospital
Oct 17, 2022

Hepatocellular Carcinoma Trial in Beijing (AK104, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Oct 17, 2022

Hepatocellular Carcinoma Trial in Hangzhou (AK104 lenvatinib, AK104)

Active, not recruiting
  • Hepatocellular Carcinoma
  • AK104 lenvatinib
  • AK104
  • Hangzhou, Zhejiang, China
    The first affilited hospital zhejiang university school of medci
Oct 17, 2022

Advanced Tumors, Lymphoma, Metastatic Tumors Trial in Changchun, Jinan (HLX301)

Recruiting
  • Advanced Tumors
  • +2 more
  • Changchun, Jilin, China
  • +1 more
Jul 12, 2022

HIV-1-infection Trial in Mbeya (ART, 10E8.4/iMab, VRC07-523LS)

Not yet recruiting
  • HIV-1-infection
  • Mbeya, Tanzania
    National Institute for Medical Research-Mbeya Medical Resarch Ce
Jun 6, 2023

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Malignant Tumor Trial in Shanghai (PM8002)

Recruiting
  • Malignant Neoplasm
  • Shanghai, Shanghai, China
    Shanghai Orient Hospital
Jun 25, 2023

SCLC,Extensive Stage Trial in Changchun (AK104 IV infusion;Chiauranib oral)

Not yet recruiting
  • SCLC,Extensive Stage
  • AK104 IV infusion;Chiauranib oral
  • Changchun, Jilin, China
    Jilin Province Cancer Hospital
Aug 16, 2022

Multiple Myeloma Trial (Teclistamab, Tocilizumab)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jul 24, 2023

Solid Tumor Trial in China (SI-B003)

Recruiting
  • Solid Tumor
  • Beijing, Beijing, China
  • +7 more
Jan 11, 2023

HER2-positive Recurrent or Metastatic Malignant Solid Tumor Trial in Zhengzhou (Recombinant Humanized Bispecific Monoclonal

Recruiting
  • HER2-positive Recurrent or Metastatic Malignant Solid Tumor
  • Recombinant Humanized Bispecific Monoclonal Antibody MBS301
  • Zhengzhou, China
    Henan Cancer Hospital
Nov 9, 2022

Primary Sjogren's Syndrome Trial in Palo Alto (tibulizumab (LY3090106))

Withdrawn
  • Primary Sjogren's Syndrome
  • tibulizumab (LY3090106)
  • Palo Alto, California
    Stanford University
Jan 12, 2022

Metastatic Solid Tumors, Esophageal Cancer, NSCLC Trial in Houston, San Antonio, Toronto (M1231)

Recruiting
  • Metastatic Solid Tumors
  • +2 more
  • Houston, Texas
  • +2 more
Jul 29, 2022

Locally Advanced or Metastatic Solid Tumors, Squamous-cell NSCLC Trial in Shanghai, Xuzhou (HLX35)

Recruiting
  • Locally Advanced or Metastatic Solid Tumors
  • Squamous-cell Non-small Cell Lung Cancer
  • Shanghai, China
  • +1 more
Jun 28, 2022

B-cell Non-Hodgkins Lymphoma (B-NHL) Trial (Odronextamab, REGN5837)

Not yet recruiting
  • B-cell Non-Hodgkins Lymphoma (B-NHL)
  • (no location specified)
Jan 5, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Cadonilimab
  • transjugular intrahepatic portosystemic shunt (TIPS)
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 30, 2023

Hepatocellular Carcinoma Trial (AK112)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Jun 24, 2022

Solid Tumor, Adult Trial in Guangzhou (AK112)

Active, not recruiting
  • Solid Tumor, Adult
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 8, 2022